MELK and pulmonary arterial hypertension: To investigate the role of MELK inhibition in pulmonary hypertension, we employed a Sugen/hypoxia (Su/H) mouse model and treated mice with the MELK inhibitor OTS167 (5 mg/kg, IP daily) or saline starting at the end of week 1 for 3 weeks (Figure 7A).